S Hense1,2, A Luque Ramos1, J Callhoff3, K Albrecht3, A Zink3,4, F Hoffmann5. 1. Department für Versorgungsforschung, Fakultät für Medizin und Gesundheitswissenschaften, Carl von Ossietzky Universität Oldenburg, Ammerländer Heerstr. 140, 26111, Oldenburg, Deutschland. 2. Abteilung für Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut, Berlin, Deutschland. 3. Programmbereich Epidemiologie, Deutsches Rheumaforschungszentrum Berlin, Berlin, Deutschland. 4. Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité Universitätsmedizin Berlin, Berlin, Deutschland. 5. Department für Versorgungsforschung, Fakultät für Medizin und Gesundheitswissenschaften, Carl von Ossietzky Universität Oldenburg, Ammerländer Heerstr. 140, 26111, Oldenburg, Deutschland. falk.hoffmann@uni-oldenburg.de.
Abstract
BACKGROUND: Rheumatoid arthritis (RA) is the most common chronic inflammatory joint disease with a prevalence of up to 1 % in the adult population. OBJECTIVE: This study describes the prevalence of RA diagnoses in outpatient health insurance claims data, based on different case definitions and stratified by age, sex and region of residence. METHODS: Based on data from a nationwide statutory health insurance fund (BARMER GEK) from the year 2013, a cross-sectional study of insurants aged 18 years or older was conducted. The following case definitions were applied: A) a diagnosis of seropositive rheumatoid arthritis (M05) or other rheumatoid arthritis (M06) according to the international classification of diseases 10 German modification (ICD-10-GM) in at least two quarterly periods of the year 2013, B) case definition A plus determination of C‑reactive protein (CRP) or erythrocyte sedimentation rate (ESR) at least once, C) case definition B plus specific drug therapy and D) case definition A plus treatment by a rheumatologist. Raw as well as age and sex-standardized prevalences were calculated and stratified according to the federal state. RESULTS: The study population consisted of 7,155,315 insurants of whom 60.2 % were female. Overall, RA prevalences for the respective case definitions were 1.62 % (A), 1.11 % (B), 0.94 % (C) and 0.64 % (D). When standardized to the German population the prevalences were 1.38 % (A), 0.95 % (B), 0.81 % (C) and 0.55 % (D). The proportion of women was approximately 80 % for all case definitions. Prevalences increased with age, peaking in the age group 70-79 years old and showing the highest values in eastern and the lowest in southern Germany for raw as well as standardized measures. CONCLUSION: Regional differences in the prevalence of RA diagnoses in health insurance claims data were observed independent of age, sex and case definition. The expected prevalence according to the results of international studies was best achieved when case definitions with CRP or ESR were considered.
BACKGROUND:Rheumatoid arthritis (RA) is the most common chronic inflammatory joint disease with a prevalence of up to 1 % in the adult population. OBJECTIVE: This study describes the prevalence of RA diagnoses in outpatient health insurance claims data, based on different case definitions and stratified by age, sex and region of residence. METHODS: Based on data from a nationwide statutory health insurance fund (BARMER GEK) from the year 2013, a cross-sectional study of insurants aged 18 years or older was conducted. The following case definitions were applied: A) a diagnosis of seropositive rheumatoid arthritis (M05) or other rheumatoid arthritis (M06) according to the international classification of diseases 10 German modification (ICD-10-GM) in at least two quarterly periods of the year 2013, B) case definition A plus determination of C‑reactive protein (CRP) or erythrocyte sedimentation rate (ESR) at least once, C) case definition B plus specific drug therapy and D) case definition A plus treatment by a rheumatologist. Raw as well as age and sex-standardized prevalences were calculated and stratified according to the federal state. RESULTS: The study population consisted of 7,155,315 insurants of whom 60.2 % were female. Overall, RA prevalences for the respective case definitions were 1.62 % (A), 1.11 % (B), 0.94 % (C) and 0.64 % (D). When standardized to the German population the prevalences were 1.38 % (A), 0.95 % (B), 0.81 % (C) and 0.55 % (D). The proportion of women was approximately 80 % for all case definitions. Prevalences increased with age, peaking in the age group 70-79 years old and showing the highest values in eastern and the lowest in southern Germany for raw as well as standardized measures. CONCLUSION: Regional differences in the prevalence of RA diagnoses in health insurance claims data were observed independent of age, sex and case definition. The expected prevalence according to the results of international studies was best achieved when case definitions with CRP or ESR were considered.
Entities:
Keywords:
Epidemiology; Health services research; Healthcare insurance data; Rheumatoid arthritis; Secondary data
Authors: F Hoffmann; F Andersohn; K Giersiepen; E Scharnetzky; E Garbe Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2008-10 Impact factor: 1.513
Authors: H Källberg; V Vieira; M Holmqvist; J E Hart; K H Costenbader; C Bengtsson; L Klareskog; E W Karlson; L Alfredsson Journal: Scand J Rheumatol Date: 2013-04-23 Impact factor: 3.641
Authors: Kathleen Chang; So Min Yang; Seong Heon Kim; Kyoung Hee Han; Se Jin Park; Jae Il Shin Journal: Int J Mol Sci Date: 2014-12-03 Impact factor: 5.923
Authors: Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde Journal: Ann Rheum Dis Date: 2015-05-12 Impact factor: 19.103
Authors: K Albrecht; A Richter; Y Meissner; D Huscher; L Baganz; K Thiele; M Schneider; A Strangfeld; A Zink Journal: Z Rheumatol Date: 2017-06 Impact factor: 1.372
Authors: A Strahl; O Schneider; J Frankenhauser-Mannuß; S Knapstein; C Hermann; B Lembeck; H-M Lorenz; W Rüther; J Flechtenmacher Journal: Z Rheumatol Date: 2018-03 Impact factor: 1.372
Authors: Carsten Oliver Schmidt; Klaus-Peter Günther; Jens Goronzy; Katinka Albrecht; Jean-François Chenot; Johanna Callhoff; Adrian Richter; Richard Kasch; Wolfgang Ahrens; Heiko Becher; Klaus Berger; Hermann Brenner; Beate Fischer; Claus-Werner Franzke; Wolfgang Hoffmann; Bernd Holleczek; Lina Jaeschke; Carsten Jenning; Karl-Heinz Jöckel; Rudolf Kaaks; Thomas Keil; Alexander Kluttig; Gérard Krause; Oliver Kuß; Michael Leitzmann; Wolfgang Lieb; Jakob Linseisen; Markus Löffler; Claudia Meinke-Franze; Christa Meisinger; Karin B Michels; Rafael Mikolajczyk; Nadia Obi; Annette Peters; Tobias Pischon; Tamara Schikowski; Sabine Schipf; Christof Specker; Henry Völzke; Kerstin Wirkner; Angela Zink; Oliver Sander Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2020-04 Impact factor: 1.513